Performance of High Mobility Protein Group 1 and Interleukin-6 as Predictors of Outcomes Resulting from Variceal Bleeding in Patients with Advanced Chronic Liver Disease

Inflammation ◽  
2021 ◽  
Author(s):  
Camilla dos Santos Pinheiro ◽  
Célio Geraldo de Oliveira Gomes ◽  
Camilla Ribeiro Lima Machado ◽  
Ludmila Resende Guedes ◽  
Henrique Carvalho Rocha ◽  
...  
2021 ◽  
Vol 3 (1) ◽  
pp. 24
Author(s):  
Decky Andrea ◽  
Luciana Rotty

Abstract: Chronic liver disease is a progressive impairment of liver function. It is caused by non-alcoholic fatty liver, viral infection of the liver, excessive alcohol consumption, metabolic diseases such as galactosemia, autoimmune disease, and the influence of chemicals. Complications that are often found are esophageal variceal bleeding, hepatorenal syndrome, and refractory ascites. Terlipressin, which is a vasopressin analogue, is currently widely used in developed countries because it has been shown to improve survival of patients with esophageal varices, hepatorenal syndrome, and refractory ascites. Terlipressin is the current standard therapy for esophageal variceal bleeding in countries where it is available.Keywords: chronic liver disease; terlipressin  Abstrak: Penyakit hati kronis (PHK) adalah gangguan fungsi hati yang terjadi secara progresif. Peyakit hati kronis di sebabkan oleh non-alcoholic fatty liver, infeksi virus pada hati, konsumsi alkohol berlebihan, peyakit metabolik seperti galaktosemia, penyakit autoimun, dan pengaruh bahan kimia. Komplikasi yang sering ditemukan pada PHK ialah perdarahan varises esofagus, sindrom hepatorenal, dan asites refrakter. Terlipressin yang merupakan analog vasopressin saat ini banyak di pakai di negara maju karena terbukti dapat meningkatkan kelangsungan hidup pasien perdarahan varises esofagus, sindrom hepatorenal, dan asites refrakter. Dewasa ini terlipressin telah menjadi terapi standar perdarahan varises esofagus di negara-negara di mana obat ini tersedia.Kata kunci: penyakit hati kronik; terlipressin


2020 ◽  
Vol 11 (SPL2) ◽  
pp. 228-234
Author(s):  
Karthick M ◽  
Prabakaran P T ◽  
Rajendran K ◽  
Gowrishankar A ◽  
Halleys Kumar E ◽  
...  

Portal hypertension is associated with liver cirrhosis and esophageal varices is a common complication. Cirrhotic liver increases resistance to the passage of blood and thereby increased splanchnic blood flow secondary to vasodilation. Prevalence of portal hypertension varies from 50-60% in patients with liver cirrhosis. The first episode of variceal bleeding causes mortality, which ranges from 40-70%. All cirrhotic patients should be screened for the oesophageal varices according to  Baveno III consensus conference on portal hypertension and recommendation for endoscopy is at 2-3 years intervals in patients without varices and at 1-2 years interval in patients with small varices in order to evaluate the development or variceal progression. But this is questionable as endoscopy is an invasive procedure and also cost-effective. Only 9-36% of patients with cirrhosis were found to have varices on screening endoscopy. Non-invasive assessment of variceal bleeding with good predictivity includes biochemical, clinical and ultrasonographic parameters. Thus unnecessary intervention is avoided and at the same time, the patients at risk of bleeding are also not missed. This study emphasizes the need for an annual ultrasonogram examination as a part of a surveillance program for screening of oesophageal varices in patients of chronic liver disease.


1992 ◽  
Vol 45 (5) ◽  
pp. 408-411 ◽  
Author(s):  
S Kakumu ◽  
A Fukatsu ◽  
T Shinagawa ◽  
S Kurokawa ◽  
A Kusakabe

Sign in / Sign up

Export Citation Format

Share Document